Physician profile
Deborah Fishkind
NPI 1225087950
$4,825.74
in general payments reported to CMS, 2019-2025
24 companies · $1,296 in 2025
The $1,296 reported for 2025 was more than what 95% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.98 · 2021: $98.72 · 2022: $899 · 2023: $979 · 2024: $1,493 · 2025: $1,296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,755 · Education: $13.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,755.11 |
| Education | $13.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $842.91 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $812.70 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $491.30 | 2021-2025 | Trulance, Xifaxan, Relistor |
| Janssen Biotech, INC. | $391.05 | 2021-2025 | Stelara, Tremfya, Simponi |
| Gilead Sciences, INC. | $338.64 | 2019-2023 | |
| Redhill Biopharma INC. | $229.21 | 2022-2024 | Talicia, Aemcolo, Movantik |
| Genzyme Corporation | $215.90 | 2022-2025 | |
| Celgene Corporation | $202.00 | 2023-2024 | Zeposia |
| Ardelyx, INC. | $182.96 | 2024-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $171.15 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $161.76 | 2023-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $150.12 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $147.51 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $102.44 | 2024-2025 | Zenpep, Vowst |
| Ferring Pharmaceuticals INC. | $67.99 | 2023-2024 | Clenpiq, Rebyota |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $56.39 | 2022-2025 | Sutab, Suflave |
| Qol Medical, LLC | $49.85 | 2019-2023 | Sucraid |
| Lilly USA, LLC | $45.85 | 2025 | Omvoh |
| Nestle Healthcare Nutrition INC. | $41.19 | 2023 | |
| Celltrion USA INC. | $31.24 | 2024 | Vegzelma, Zymfentra |
| Pfizer INC. | $30.02 | 2019-2025 | |
| Medtronic, INC. | $24.47 | 2024 | |
| Mallinckrodt Hospital Products INC. | $23.25 | 2023 | Terlivaz |
| Blueprint Medicines Corporation | $15.84 | 2024 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Fishkind listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.